About Heterogeneous nuclear ribonucleoprotein F
Heterogeneous nuclear ribonucleoprotein F (HNRNPF) is a protein
from Homo sapiens identified by UniProt accession
P52597, 415 residues long.
MolForge cross-references it against 0 known binders and
64 disease associations.
Target properties
| Protein name | Heterogeneous nuclear ribonucleoprotein F |
| UniProt accession | P52597 |
| Gene | HNRNPF |
| Organism | Homo sapiens |
| Length | 415 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (64)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.52
- eosinophil count · score 0.35
- platelet count · score 0.34
- blood urea nitrogen measurement · score 0.29
- HbA1c measurement · score 0.28
- serum urea measurement · score 0.28
- glioblastoma multiforme · score 0.24
- lung adenocarcinoma · score 0.23
- breast adenocarcinoma · score 0.23
- eosinophil percentage of leukocytes · score 0.19
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P52597-F1 | alphafold | PREDICTED | 64.49 | — |
Amino-acid sequence (415 residues)
MMLGPEGGEG FVVKLRGLPW SCSVEDVQNF LSDCTIHDGA AGVHFIYTRE GRQSGEAFVE LGSEDDVKMA LKKDRESMGH RYIEVFKSHR TEMDWVLKHS GPNSADSAND GFVRLRGLPF GCTKEEIVQF FSGLEIVPNG ITLPVDPEGK ITGEAFVQFA SQELAEKALG KHKERIGHRY IEVFKSSQEE VRSYSDPPLK FMSVQRPGPY DRPGTARRYI GIVKQAGLER MRPGAYSTGY GGYEEYSGLS DGYGFTTDLF GRDLSYCLSG MYDHRYGDSE FTVQSTTGHC VHMRGLPYKA TENDIYNFFS PLNPVRVHIE IGPDGRVTGE ADVEFATHEE AVAAMSKDRA NMQHRYIELF LNSTTGASNG AYSSQVMQGM GVSAAQATYS GLESQSVSGC YGAGYSGQNS MGGYD
Explore Heterogeneous nuclear ribonucleoprotein F with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets